Project Details
| Status | Active |
|---|---|
| Effective start/end date | 1/07/21 → 1/05/27 |
Funding
- Iqvia Ltd: £413,245.52
- Iqvia Ltd: £8,918.54
EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists
- Colhoun, Helen (Principal Investigator)
- Colhoun, Helen (Principal Investigator)
- McKeigue, Paul (Co-investigator)